Hematologic and molecular responses to generic Imatinib in patients with chronic myeloid leukemia

Razmkhah, Farnaz, Razavi, Mohsen, Zaker, Farhad, Kazemi, Ahmad, Negari, Shahin, Rasighaemi, Parisa, Kalantarmotamedi, Mojdeh, Zarei, Mina and Pazhakh, Vahid 2010, Hematologic and molecular responses to generic Imatinib in patients with chronic myeloid leukemia, Laboratory medicine, vol. 41, no. 9, pp. 547-550, doi: 10.1309/LMR1KA61JYKUXRDX.

Attached Files
Name Description MIMEType Size Downloads

Title Hematologic and molecular responses to generic Imatinib in patients with chronic myeloid leukemia
Author(s) Razmkhah, Farnaz
Razavi, Mohsen
Zaker, Farhad
Kazemi, Ahmad
Negari, Shahin
Rasighaemi, Parisa
Kalantarmotamedi, Mojdeh
Zarei, Mina
Pazhakh, Vahid
Journal name Laboratory medicine
Volume number 41
Issue number 9
Start page 547
End page 550
Total pages 4
Publisher Oxford University Press
Place of publication Oxford, Eng.
Publication date 2010-09
ISSN 0007-5027
1943-7730
Keyword(s) chronic myeloid leukemia
molecular response
hematologic response
Imatib
Summary Background: Imatinib mesylate is a drug used in treating chronic myeloid leukemia (CML). It induces apoptosis and inhibits cell proliferation. This study aimed to evaluate hematologic and molecular responses to Imatib (Cipla Limited, Mumbai, India) in 30 chronic phase CML patients. Methods: Physical examination, CBC test, and peripheral blood smear were performed in order to assess the hematologic response in patients. Molecular response was evaluated through quantitative assessment of BCR-ABL fusion gene expression by real-time reverse transcriptase polymerase chain reaction (RT-PCR). The correlation of molecular and hematologic responses with the patient's age and sex and also with dosage and duration of Imatib consumption was analyzed statistically. Results: Ninety percent of the patients showed some sort of hematologic response that had no significant correlation with a patient's age or sex, dosage, or duration of Imatib consumption (P>0.05). Overall, 46.7% of patients showed complete molecular response (CMR), 43.3% showed partial molecular response, and 10% showed no molecular response (NMR) to Imatib. A reverse significant correlation was noted between the type of molecular response and patient's age (P<0.05). In contrast, no significant correlation was found between the type of molecular response and patient's sex, dosage, or duration of Imatib consumption (P>0.05). Conclusion: Our study results indicate that molecular and hematologic responses to Imatib were acceptably good and therefore its efficacy is comparable to that of more expensive brands like Gleevec.
Language eng
DOI 10.1309/LMR1KA61JYKUXRDX
Indigenous content off
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2010, Oxford University Press
Persistent URL http://hdl.handle.net/10536/DRO/DU:30119493

Document type: Journal Article
Collection: Deakin Research
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 11 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 45 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Fri, 08 Mar 2019, 10:20:13 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.